Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: A retrospective case series

IF 1.9 2区 农林科学 Q2 AGRICULTURE, DAIRY & ANIMAL SCIENCE Domestic animal endocrinology Pub Date : 2024-11-19 DOI:10.1016/j.domaniend.2024.106894
Tania Sundra , Edd Knowles , David Rendle , Erin Kelty , Guy Lester , Gabriele Rossi
{"title":"Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: A retrospective case series","authors":"Tania Sundra ,&nbsp;Edd Knowles ,&nbsp;David Rendle ,&nbsp;Erin Kelty ,&nbsp;Guy Lester ,&nbsp;Gabriele Rossi","doi":"10.1016/j.domaniend.2024.106894","DOIUrl":null,"url":null,"abstract":"<div><div>The metabolic and lipid profiles of horses treated with sodium-glucose cotransporter 2 inhibitors are not well understood. This retrospective study evaluated blood parameters in hyperinsulinemic horses treated with either ertugliflozin (0.05 mg/kg) or dapagliflozin (0.02 mg/kg) orally once daily. Blood samples were collected at baseline (day 0) and after 7 and/or 30 days of treatment. Statistical analyses were conducted using Wilcoxon signed-rank, Mann-Whitney and Spearman's rank correlation tests. Thirty-four horses received dapagliflozin and 24 received ertugliflozin. Significant (p&lt;0.05) within-horse changes between day 0 and day 30 included [median, inter-quartile range (IQR)]: basal serum [Insulin] (uU/ml) reduced 170 (92-280) to 28.7 (14.5-90); [triglycerides] (mmol/l) increased 0.5 (0.3-0.6) to 1.0 (0.6-1.56), [β-hydroxybutyrate] (umol/l) increased 0.22 (0.17-2.7) to 0.30 (0.24-0.35); [total cholesterol] (mmol/l) increased 2.36 (2-2.6) to 2.84 (2.4-3.7); and GGT (IU/ml) increased 21 (16-32) to 25 (18-38). As a percentage of total serum lipids, high-density lipoprotein (HDL) reduced 52.4 % (47.9 %-61.0 %) to 50 % (41 %-54.8 %) and very-low density lipoprotein (VLDL) increased 10.4 % (6.4 %-14.4 %) to 12.3 % (9.9 %-16.8 %) (all p&lt;0.05). Differences between ertugliflozin and dapagliflozin groups were not significant in any of these parameters at days 0, 7 or 30. At day 30, 10/48 (21 %) cases had [triglycerides] &gt; 2.0 mmol/l (maximum = 10.8mmol/l). Day 30 [triglyceride] correlated with day 0: basal insulin (rho=0.47); [triglyceride] (rho=0.42); %VLDL (rho=0.34) day 30: [total cholesterol] (rho=0.67), %HDL (rho=-0.432) and %VLDL (rho=0.708). Our findings suggest that SGLT2 inhibitors induce minor changes in lipid profiles, with occasional cases of marked hypertriglyceridemia, and that dapagliflozin and ertugliflozin exhibit similar biochemical effects.</div></div>","PeriodicalId":11356,"journal":{"name":"Domestic animal endocrinology","volume":"90 ","pages":"Article 106894"},"PeriodicalIF":1.9000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Domestic animal endocrinology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0739724024000572","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"AGRICULTURE, DAIRY & ANIMAL SCIENCE","Score":null,"Total":0}
引用次数: 0

Abstract

The metabolic and lipid profiles of horses treated with sodium-glucose cotransporter 2 inhibitors are not well understood. This retrospective study evaluated blood parameters in hyperinsulinemic horses treated with either ertugliflozin (0.05 mg/kg) or dapagliflozin (0.02 mg/kg) orally once daily. Blood samples were collected at baseline (day 0) and after 7 and/or 30 days of treatment. Statistical analyses were conducted using Wilcoxon signed-rank, Mann-Whitney and Spearman's rank correlation tests. Thirty-four horses received dapagliflozin and 24 received ertugliflozin. Significant (p<0.05) within-horse changes between day 0 and day 30 included [median, inter-quartile range (IQR)]: basal serum [Insulin] (uU/ml) reduced 170 (92-280) to 28.7 (14.5-90); [triglycerides] (mmol/l) increased 0.5 (0.3-0.6) to 1.0 (0.6-1.56), [β-hydroxybutyrate] (umol/l) increased 0.22 (0.17-2.7) to 0.30 (0.24-0.35); [total cholesterol] (mmol/l) increased 2.36 (2-2.6) to 2.84 (2.4-3.7); and GGT (IU/ml) increased 21 (16-32) to 25 (18-38). As a percentage of total serum lipids, high-density lipoprotein (HDL) reduced 52.4 % (47.9 %-61.0 %) to 50 % (41 %-54.8 %) and very-low density lipoprotein (VLDL) increased 10.4 % (6.4 %-14.4 %) to 12.3 % (9.9 %-16.8 %) (all p<0.05). Differences between ertugliflozin and dapagliflozin groups were not significant in any of these parameters at days 0, 7 or 30. At day 30, 10/48 (21 %) cases had [triglycerides] > 2.0 mmol/l (maximum = 10.8mmol/l). Day 30 [triglyceride] correlated with day 0: basal insulin (rho=0.47); [triglyceride] (rho=0.42); %VLDL (rho=0.34) day 30: [total cholesterol] (rho=0.67), %HDL (rho=-0.432) and %VLDL (rho=0.708). Our findings suggest that SGLT2 inhibitors induce minor changes in lipid profiles, with occasional cases of marked hypertriglyceridemia, and that dapagliflozin and ertugliflozin exhibit similar biochemical effects.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高胰岛素血症马匹接受达帕格列净或ertugliflozin治疗后的短期临床和生化反应:回顾性病例系列
人们对接受钠-葡萄糖共转运体 2 抑制剂治疗的马匹的代谢和血脂状况还不甚了解。这项回顾性研究评估了高胰岛素血症马匹的血液参数,这些马匹每天口服一次ertugliflozin(0.05 mg/kg)或dapagliflozin(0.02 mg/kg)。在基线(第0天)和治疗7天和/或30天后采集血液样本。采用Wilcoxon符号秩检验、Mann-Whitney检验和Spearman秩相关检验进行统计分析。34匹马接受了达帕格列净治疗,24匹马接受了ertugliflozin治疗。第 0 天和第 30 天之间马匹内部的显著变化(p<0.05)包括[中位数,四分位数间距 (IQR)]:基础血清[胰岛素](uU/ml)从 170(92-280)降至 28.7(14.5-90);[甘油三酯](mmol/l)从 0.5(0.3-0.6)升至 1.0(0.6-1.56),[β-羟丁酸](umol/l)升至 0.30(0.24-0.35),[总胆固醇](mmol/l)升至 2.36(2-2.6),[GGT](IU/ml)升至 25(18-38)。高密度脂蛋白(HDL)占血清总脂类的百分比从 52.4% (47.9 %-61.0 %) 降至 50% (41 %-54.8 %),极低密度脂蛋白(VLDL)从 10.4% (6.4 %-14.4 %) 升至 12.3% (9.9 %-16.8 %)(所有 p<0.05)。在第0天、第7天或第30天,ertugliflozin组和dapagliflozin组在这些参数上的差异均不显著。第 30 天,10/48 例(21%)患者的[甘油三酯]为 2.0 毫摩尔/升(最大值 = 10.8 毫摩尔/升)。第 30 天的[甘油三酯]与第 0 天的相关性:基础胰岛素(rho=0.47);[甘油三酯](rho=0.42);%VLDL(rho=0.34);第 30 天的相关性:[总胆固醇](rho=0.67)、%HDL(rho=-0.432)和%VLDL(rho=0.708)。我们的研究结果表明,SGLT2 抑制剂会引起血脂谱的轻微变化,偶尔会出现明显的高甘油三酯血症,达帕格列酮和厄曲酶会产生类似的生化效应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Domestic animal endocrinology
Domestic animal endocrinology 农林科学-奶制品与动物科学
CiteScore
5.50
自引率
4.80%
发文量
58
审稿时长
31 days
期刊介绍: Domestic Animal Endocrinology publishes scientific papers dealing with the study of the endocrine physiology of domestic animal species. Those manuscripts utilizing other species as models for clinical or production problems associated with domestic animals are also welcome. Topics covered include: Classical and reproductive endocrinology- Clinical and applied endocrinology- Regulation of hormone secretion- Hormone action- Molecular biology- Cytokines- Growth factors
期刊最新文献
Distribution and sequence analysis of the melanocortin 2 receptor in horses and ponies The structure of the porcine uterine-conceptus interface is associated with gestational day, fetal size and sex Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: A retrospective case series Effect of short-term dopamine reduction on insulin sensitivity and post-prandial insulin and glucose responses in Standardbred horses Effects of rumen metabolite butyric acid on bovine skeletal muscle satellite cells proliferation, apoptosis and transcriptional states during myogenic differentiation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1